A share price of Moderna Inc [MRNA] is currently trading at $34.3, up 1.30%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRNA shares have gain 11.15% over the last week, with a monthly amount glided 21.46%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Jefferies started tracking the stock with Hold rating on December 12, 2025, and set its price target to $30. On March 13, 2025, Citigroup initiated with a Neutral rating and assigned a price target of $40 on the stock. Barclays downgraded its rating to a Equal Weight and decreased its price target to $45 on February 18, 2025. Goldman downgraded its rating to a Neutral and reduced its price target to $51 on January 29, 2025. Argus downgraded its rating to Hold for this stock on December 18, 2024.
Moderna Inc experienced fluctuations in its stock price throughout the past year between $22.28 and $45.40. Currently, Wall Street analysts expect the stock to reach $30.73 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $34.3 at the most recent close of the market. An investor can expect a potential drop of -10.41% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Trailing Twelve Months sales for Moderna Inc [NASDAQ:MRNA] were 2.23B which represents -45.44% decline. Gross Profit Margin for this corporation currently stands at 0.12% with Operating Profit Margin at -1.56%, Pretax Profit Margin comes in at -1.42%, and Net Profit Margin reading is -1.4%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.31 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Moderna Inc [NASDAQ:MRNA] is 3.93. As well, the Quick Ratio is 3.73, while the Cash Ratio is 0.67. Considering the valuation of this stock, the price to sales ratio is 5.93, the price to book ratio is 1.44.
Transactions by insiders
Recent insider trading involved AFEYAN NOUBAR, Director, that happened on Dec 11 ’25 when 23853.0 shares were sold. Affiliate, Flagship Pioneering Inc. completed a deal on Dec 11 ’25 to buy 23853.0 shares. Meanwhile, Director Hussain Abbas sold 504.0 shares on Dec 09 ’25.
